Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study

Area of Science:

• Osteoporosis research
• Pharmacological interventions for bone health

Background:

• Low bone mass (osteopenia) increases fracture risk.
• Effective therapeutic strategies for increasing bone mineral density are crucial.

Purpose of the Study:

• To evaluate the efficacy of combined sodium monofluorophosphate and calcium (FC) therapy in enhancing lumbar bone mineral density (BMD).
• To assess the safety and effectiveness of FC therapy in patients with severe osteopenia.

Main Methods:

• Prospective, double-masked, randomized study involving 94 patients aged 50-70 years with low lumbar BMD.
• Patients received either FC (13.2 mg F-, 500 mg Ca2+) or calcium alone (C, 500 mg Ca2+) twice daily for 2 years.
• Lumbar BMD measured using dual photon absorptiometry; response defined as BMD increase > 0.034 g/cm2.

Main Results:

• FC therapy resulted in a statistically significant increase in mean lumbar BMD compared to calcium alone.
• FC-treated patients showed a mean BMD increase of 7.1% per year, confirmed by ANOVA.
• 71.4% of FC-treated patients achieved a significant BMD increase, indicating treatment effectiveness.

Conclusions:

• Combined sodium monofluorophosphate and calcium therapy is effective in increasing lumbar BMD in patients with low bone mass.
• The dosage of 26.4 mg fluoride ion/day (200 mg monofluorophosphate/day) is safe and beneficial for improving bone density.
• FC therapy represents a viable option for managing severe osteopenia and potentially reducing fracture risk.